Next Article in Journal
Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer
Previous Article in Journal
New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases
Previous Article in Special Issue
The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists
Open AccessReview

Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis

1
Division of Cardiovascular Medicine and the Gill Heart Institute, University of Kentucky, Lexington, KY 40536, USA
2
Lexington VA Medical Center, Lexington, KY 40536, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(8), 915-928; https://doi.org/10.3390/ph6080915
Received: 6 May 2013 / Revised: 18 July 2013 / Accepted: 26 July 2013 / Published: 2 August 2013
(This article belongs to the Special Issue GPCR Based Drug Discovery)
Platelets contribute fundamentally to ischemic heart disease, and antiplatelet therapy has been critical to reducing acute thrombotic complications of atherosclerotic disease. Thrombin, by acting on protease activated receptors (PAR), is one of the most potent platelet activators. PAR-1 antagonists may therefore provide more comprehensive antithrombotic effects. We review the pathophysiology of atherothrombosis, platelet activation by thrombin, the role of platelet protease activated receptors (PAR), and the clinical data supporting their use. View Full-Text
Keywords: platelets; thrombin; thrombosis; protease-activated receptors platelets; thrombin; thrombosis; protease-activated receptors
Show Figures

Figure 1

MDPI and ACS Style

Wallace, E.L.; Smyth, S.S. Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis. Pharmaceuticals 2013, 6, 915-928.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop